SABCS 40th Annual Meeting
The 40th Annual San Antonio Breast Cancer Symposium will take place from December 5-9 in the Henry B Gonzalez Convention Center. Breast cancer clinicians and researchers will convene to discuss cutting-edge treatment options and novel strategies for managing breast cancer. Journal of Clinical Pathways will be highlighting many of the key presentations from the meeting.
Elderly patients with untreated early-stage triple-negative breast cancer exhibited a higher mortality rate than patients treated with neoadjuvant or adjuvant therapy.
Women with HER2-positive and triple-negative breast cancer have an elevated risk of developing brain metastasis regardless of active systemic treatment receipt.
Re-excision rates following breast-conserving surgery have significantly declined in the wake of professional society guideline implementation.
Women with HER2-positive breast cancer who received sequential trastuzumab did not experience a significant difference in OS or RFS when compared with women who received concurrent therapy.
The use of digital breast tomosynthesis decreased false positive rates while increasing true negative rates when compared with traditional digital mammography.
Non-Hispanic black patients with localized breast cancer who received neoadjuvant chemotherapy experienced worse distant relapse-free survival outcomes when compared with non-Hispanic white patients.
Weight loss was associated with a reduced risk for breast cancer among postmenopausal women.
Overall costs of radiation therapy for early-stage breast cancer do not burden the health care system when analyzed in relation to survival benefit.